Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Singh says Japanese pharma giant's allegations false.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Last week, to study the market, Coca-Cola introduced promotional 750-ml PET bottles for Rs 30, the price point of 600-ml PET bottles, across its portfolio of Coke, Sprite, Thums Up, Fanta and Limca, primarily in metro cities.
Dinesh Thakur says he waved the red flag only after Ranbaxy didn't respond to his concerns.
The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Bharti was talking to Standard Chartered Bank and Citibank, among others, to manage the issue.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
This is going to be the lowest price for a Coke product in the non-returnable ready-to-drink category.
Data contradict Swiss drug major's claim that India does not respect IPR.
Says tradability will ensure greater economic efficiency & higher revenues for the government.
In talks with BSNL, MTNL to float a firm in which it will hold 49 per cent.
DoT's data is based on inputs from the Telecom Regulatory Authority of India and service providers.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances